NCT02392611View on ClinicalTrials.gov

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

March 16, 2015

Primary Completion Date

October 11, 2017

Study Completion Date

October 11, 2017

Conditions
Solid Tumors and Lymphomas
Interventions
DRUG

Alobresib

Tablet administered orally once daily on Study Day 1 through Cycle 1 Day 28 of 28 days cycle

DRUG

Exemestane

Tablets administered orally once daily on Cycle 1 Day 1 of 28 days cycle

DRUG

Fulvestrant

Administered intramuscularly on Cycle 1 Day 1 of 28 days cycle and every 28 days

Trial Locations (4)

Unknown

Scottsdale

Fort Wayne

Goshen

San Antonio

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT02392611 - Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer | Biotech Hunter | Biotech Hunter